Tanshinone IIA Alleviates Atherosclerosis Through Inhibition of NF-κB and PPARαE/ABCA1 Signaling Pathways

作者：He, Dequan; Zhang, Jiawei; Chen, Youquan; Li, Zhiliang^*

来源：Journal of Biomedical Nanotechnology, 2023, 19(10): 1824-1831.

DOI：10.1166/jbn.2023.3689

• Tanshinone IIA
• NF-kappa B
• PPAR alpha/ABCA1
• Inflammatory Response
• Lipid Deposition
• Atherosclerosis Tanshinone IIA
• Atherosclerosis

This study evaluated the role and underlying mechanisms of Tanshinone IIA (Tan IIA) in atherosclerosis. C57BL mice (control group) and ApoE mice (model group) were administered a conventional and high-fat diet for 20 weeks. The Tan IIA group was obtained by administering a high-fat diet plus 8 weeks of Tan IIA to other mice for 20 weeks, followed by oil red O staining and lipid examination. RAW264.7 cells were transfected with PPAR alpha siRNA+Tan IIA to measure their expression. The results showed little change in body weight between the three groups (P < 0.05). Liver index was significantly increased in the model and Tan IIA groups (P <0.05). Atherosclerotic plaques, plaque cross-sectional area, human oxidized low-density lipoprotein (ox-LDL), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels, p-NF-kappa B, p-IKK alpha, P-Ikk alpha/beta, TNF-alpha and IL-1 beta levels were significantly increased in the model group and decreased in the Tan IIA group (P < 0.05). We also noted a decrease in PPAR alpha, PGC-1 alpha and ABCA1 in the model group and an increase in the Tan IIA group. NF-kappa B expression was increased in the nucleus and decreased in the cytoplasm in the model group, which was reversed by Tan IIA treatment. Tan IIA significantly reduced ox-LDL, LDL-C and TG levels, plaque size and plaque cross-sectional area in atherosclerosis. Tan IIA effectively inhibited NF-kappa B, activated the PPAR alpha/ABCA1 signalling pathway, and reduce inflammatory pathways, thereby improving lipid deposition and acting as an anti-atherosclerotic agent.

• 单位
  广州医学院; 南方医科大学